Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $64,264.20 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 2,145 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $29.96, for a total value of $64,264.20. Following the completion of the transaction, the insider now owns 52,011 shares of the company’s stock, valued at approximately $1,558,249.56. This represents a 3.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Apellis Pharmaceuticals Trading Up 0.7 %

APLS stock opened at $30.13 on Wednesday. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90. The company has a market capitalization of $3.75 billion, a PE ratio of -14.84 and a beta of 0.94. The company’s 50-day simple moving average is $31.89 and its 200 day simple moving average is $33.31. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The business had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.17) earnings per share. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on APLS. Royal Bank of Canada reissued a “sector perform” rating and issued a $26.00 price objective on shares of Apellis Pharmaceuticals in a report on Tuesday. Citigroup decreased their price objective on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Piper Sandler lowered their price objective on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Scotiabank reduced their price target on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a report on Wednesday, November 6th. Finally, Bank of America dropped their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of New Jersey Common Pension Fund D increased its position in shares of Apellis Pharmaceuticals by 6.6% in the second quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock worth $1,735,000 after purchasing an additional 2,820 shares during the period. Envestnet Asset Management Inc. increased its holdings in Apellis Pharmaceuticals by 42.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after buying an additional 39,931 shares during the period. Amalgamated Bank raised its position in shares of Apellis Pharmaceuticals by 5.4% in the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after buying an additional 359 shares in the last quarter. Profund Advisors LLC lifted its holdings in shares of Apellis Pharmaceuticals by 90.7% during the 2nd quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock worth $1,648,000 after acquiring an additional 20,435 shares during the period. Finally, HighVista Strategies LLC boosted its position in shares of Apellis Pharmaceuticals by 4.1% during the 2nd quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock worth $290,000 after acquiring an additional 300 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).